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Abstract: Anorectal melanoma (AM) is a rare malignancy, characterized by aggres-
sive behavior and a poor prognosis. AM is more frequent in female patients aged 
over 50 years. AM accounts for 0.4–1.6% of all melanomas, 23.8% of all mucosal 
melanomas, and 1% of all anorectal malignant tumors. There are many theories 
regarding AM pathogenesis. Some consider that AM may be related to oxidative 
stress in the region and/or to immunosuppression. Others propose that AM may 
derive from Schwannian neuroblastic cells or cells of the amine-precursor uptake 
and decarboxylation system of the gut. Assessment of pigmented lesions located 
on hidden areas is difficult. Together with late and nonspecific signs and symp-
toms which usually occur only in conjunction with large masses, diagnosis 
of  these mucosal melanomas is often delayed. Most frequently, the signs and 
symptoms are obstruction, rectal bleeding, pain, or rectal tenesmus. There are 
various histological variants of AM: epithelioid, spindle cell, lymphoma-like, and 
pleomorphic. Surgery (abdominoperineal resection or local excision) is the most 
Anorectal Melanoma84
effective treatment for AM; however, this is not associated with improved overall 
survival. Recurrence is more frequent in cases of anorectal and  rectal involvement 
when compared with anal-only involvement. There is currently no consensus 
about the most appropriate systemic treatment. The efficacy of some protocols 
previously used in patients with cutaneous melanomas is currently being studied 
in mucosal melanoma.
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INTRODUCTION
Anorectal melanoma (AM) is a rare malignancy which is often difficult to diagnose 
due to the hidden site. This malignancy is characterized by aggressive behavior, 
and patients often have a very poor prognosis, which is related to the frequent 
delay in the diagnosis, as well as biological differences in malignant melanocytes 
of this anatomic area compared to other sites. Since AM accounts for only 1% of 
all anorectal malignant tumors (1), few studies of AM have been conducted, with 
few available data for physicians and for researchers. Correct and early diagnosis, 
with subsequent multidisciplinary management, is important for improving the 
quality of life and prognosis of these patients (1). In this chapter, we investigate 
the main epidemiological, pathophysiological, genetic, clinical, and pathological 
features of AM, as well as therapeutic options.
EPIDEMIOLOGY
In 1857, Moore reported the first case of AM (2). The US National Cancer Database 
stated that mucosal melanoma represents the third most common site of primary 
melanomas after the skin and eye, and the anorectal canal is the second most 
 frequent mucosal site for melanoma after the head and neck (3, 4). Compared to 
cutaneous melanoma (CM), primary gastrointestinal melanoma is extremely rare. 
The most common gastrointestinal localization is the anorectal tract (>50%), fol-
lowed by the stomach, small intestine, and colon. It is important to highlight that 
the rectal localization is more frequent than the anal; nevertheless, the two entities 
are studied together. AM accounts for 0.4–M accounts for 0.4was and represents 
23.8% of all mucosal melanomas (1). It is more frequent in females compared to 
males (2:1 ratio) and the mean age at diagnosis is 54.5 years (5).
There is a lower incidence of mucosal melanomas in dark-pigmented indi-
viduals, possibly related to the antioxidant properties of melanin rather than its 
photo-screening effects (Table 1) (6). According to Micu et al. (3) and Ragnarsson-
Olding et  al. (7), although the incidence rate of CM has increased in recent 
decades, the incidence of AM has remained constant. Ragnarsson-Olding et al. 
found that the age-standardized incidence of AM was stable between 1960 and 
1999, at approximately 1.0 and 0.7 per million in females and males, respec-
tively, in contrast to an increasing incidence of CMs (7). Micu et  al. demon-
strated that the incidence rate of AM in Norway was 0.48 per million in the 
period between 1987 and 2007 and 0.35 per million in the period between 
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1966 and 1986. This difference was not statistically significant. In contrast, the 
incidence rate of CM increased from 103 per million between 1966 and 1986, 
to 217 per million between 1987 and 2007 (P < 0.001) (3).
In Queensland, Australia, which has the highest incidence rate of CM in the 
world, Miller et al. (8) did not find any significant differences in the incidence rate 
of AM compared to other geographical regions (8). Increased incidence of AM has 
been reported in some regions of the United States in recent years, perhaps due to 
some other etiological factors like HIV infection (4). Overall survival of this AM is 
poor, with a 5-year overall survival ranging between 10 and 20%, which is thought 
to be a consequence of late diagnosis (4).
PATHOGENESIS AND GENETICS OF AM
Melanocytes migrate from the neural crest or from the mucocutaneous junctions 
to the cutis (9–11). However, although melanin synthesis is the principal function 
of melanocytes, its role in mucosal areas is mainly characterized by antioxidant 
activity and contributing to the regional immune response (9–11). Accordingly, 
the malignant transformation in anorectal areas may be related to oxidative stress 
in these regions and/or to immunosuppression. This is also explained by the 
observation that AM often arises in patients aged >50 years (9). However, other 
valid theories have been postulated, describing that AM, as well as gastrointestinal 
melanoma, may derive from Schwannian neuroblastic cells of the autonomic 
intestinal innervation system or from the cells of the amine-precursor uptake and 
decarboxylation (APUD) system of the gut. APUD cells are involved in the uptake 
of precursors of biologically active amines, production of active amines through 
subsequent intracellular decarboxylation, and storage of the amine product in 
secretory vesicles (10). Their developmental lineage derives from neuroectoderm. 
During embryogenesis, the upper part of the embryonic plate (ectoderm) devel-
ops into skin and nervous tissue, while the lower part (endoderm) forms the gut 
lining and structures branching off this lining (5, 10). A part of the ectoderm 
(neural crest) which flanks the region forming the spinal cord and brain contains 
cells that migrate through the embryo to form various structures, including the 
skin (5, 10). Four APUD cell types have been described: β cell (secreting insulin), 
PP cell (secreting pancreatic polypeptide), α cell (secreting glucagon), and δ cell 
(secreting somatostatin) (10).
TABLE 1 Epidemiology of primary mucosal melanoma
Primary mucosal melanoma Case/million/year
Conjunctival 0.5/million/year
Sinonasal 0.5/million/year
Anorectal 0.4/million/year
Oral 0.2/million/year
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Melanocytes are detected normally in the anal squamous zone and, sporadi-
cally, in the anal transition zone. This localization is probably linked to the pres-
ence of melanocytes in the epithelial lining of the dentate line, which extends 
proximally to the rectum. Another valid theory is the hormonal one. Indeed, a 
higher female incidence has been reported in extracutaneous melanoma and in 
AM, potentially due to the involvement of estrogens in the pathogenesis of mela-
noma. However, there is no solid evidence regarding the role of female sex hor-
mones in melanoma risk. Notwithstanding, estrogens are known to increase the 
number of melanocytes and modify their melanin content (9, 12–15).
Melanoma of shield sites and of extracutaneous sites is not influenced by ultra-
violet (UV) radiation (9, 16–20). The absence of stem-cell niche in the bulge region 
in melanomas of glabrous skin could explain the pathogenesis of this malignancy in 
this anatomical region. These melanomas demonstrate aggressive behavior regard-
less of diagnostic delay. In this regard, other factors such as biological differences 
between melanocytes of this anatomical region and cutaneous melanocytes could 
play a crucial role in the pathogenesis of mucosal melanoma. Furthermore, UV 
radiation, probably via its role in vitamin D photosynthesis in exposed skin, may 
have a systemic protective effect against melanomas. However, in a recent study, we 
found a decrease of vitamin D receptor (VDR) in shield-site melanomas compared 
to nonshield-site melanomas (as chronically sun-exposed anatomic sites or inter-
mittent sun-exposed areas) (16), and lower serological levels of vitamin D in 
patients with shield-site melanomas, compared to nonshield-site melanomas (19). 
All these findings confirm that other pathways are involved in the pathogenesis of 
shield-site melanomas, as well as in noncutaneous melanomas.
GENETICS
Because of the rarity of primary mucosal melanoma (PMM), its genetic basis is still 
unclear. As reported by several authors (21–24), PMM shows distinctive charac-
teristics in comparison with CM. As reported by Edwards et al., no exon 15 BRAF 
mutations has been detected in a series of 13 PMM (23), while a mutation rate of 
33% in CM has been described in the literature (21). Furthermore, in a recent 
review by Ascierto et al., it has been reported that the BRAF mutation rate was 
only 3% in PMM (24). This finding suggests that the prevalence of BRAF muta-
tions in melanoma could depend on the anatomical origin of the tumor, probably 
in direct relation to the extent of sun exposure (23). Furthermore, the absence of 
BRAFV600E mutations suggests that the BRAF inhibitors (as vemurafenib and dab-
rafenib) would not be effective in the treatment of PMM (24). It has also been 
reported that oncogenic mutation in the NRAS gene is rarely described in PMM, 
while it has been detected in 19–28% of CM (24). Furthermore, mutations in 
GNAQ and GNAII have been described as important triggers in melanoma patho-
genesis, but they have been rarely described in PMM (24). Moreover, PMM shows 
a low frequency of KIT mutations (7–8%) and cyclin D1 amplification (10%) but 
at the same time a high rate of c-Myc amplifications (62.5%) (22).
It has been speculated that human papilloma virus (HPV) could lead to a 
higher genomic instability in PMM, supporting the degradation of the p53 pro-
tein. However, Dahlgren et  al. evaluated with PCR the presence of HPV DNA 
Paolino G et al. 87
in 15 AM, detecting no HPV DNA in these specimens (25), thereby concluding 
that the 36 HPV-tested subtypes did not play a pivotal role in the development of 
AM (25). It has also been speculated that human herpesvirus (HHV)-8 could be 
involved in the pathogenesis of PMM and specifically in AM, because of the 
 production of IL-6 by the virus. Indeed, IL-6 plays a central role in stimulating the 
proliferation of melanoma cells (26). However, the analysis of Helmke et  al. 
detected no involvement of HHV-8 in developing melanoma of the anorectal 
area  (27). Indeed, HHV-8 DNA was not found in 12 AMs by the specific and 
highly sensitive PCR assay (27).
A small rate of BRAFV599E mutation, which occurs up to 75% in CM, has been 
reported in PMM (<10%) (28). BRAF, which is located on chromosome 7q34, 
encodes a serine/threonine kinase, regulating proliferation and differentiation via 
the MAPK pathway. The V599E mutation causes the hyperactivation of BRAF 
kinase activity. As reported by Helmke et al., BRAF exon 15 mutation has been 
not detected in AM (29). Edwards et al. also detected no BRAF exon 15 mutation 
in 13 PMM, including 4 AM (23). These findings corroborate the evidence that 
PMM does not share molecular features with CM. Furthermore, the lack of BRAF 
mutations in PMM suggests that the BRAF mutations in melanoma are influenced 
by the extent of sun exposure. In addition, as reported above, these findings sug-
gest that BRAF/MEK inhibitors may not be useful in the therapy of PMM, as well 
as for AM (23).
It has been reported that up to 40% of AM shows KIT mutation (21). This 
percentage is higher than that reported in melanoma of the head/neck, as 
described by Beadling et al. (30). However, Antonescu et al. found only 23% of 
KIT mutation in AM (31). c-KIT plays a pivotal role in growth, differentiation, 
migration, and proliferation of melanocytes. It is also involved in activation of 
several cellular signaling pathways, including the phosphoinositide 3-kinase/
AKT, mitogen-activated protein kinase, Janus kinase, leading to cancer progres-
sion and extension. Most of KIT mutations in PMM occurred within exon 11, 
which encodes the juxtamembrane domain of the KIT receptor. Furthermore, a 
minority of mutations were detected also in the exon 17, which encodes the 
tyrosine kinase-2 domain of KIT (31). In addition, Omholt et al. reported BRAF 
mutation in 4.5% of AM and NRAS mutation in 4.5% of AM (32). However, no 
impact of KIT and NRAS mutations on clinical outcome has been reported by 
these authors (31, 32). In contrast, Kong et al. demonstrated reduced survival in 
melanoma patients with KIT mutations in a large-scale analysis (33). In a study 
conducted on 44 specimens, Satzger et  al. reported KIT mutations in 86% of 
AMs (34). The high percentage of mutation was observed in the juxtamembrane 
area of KIT, encoded by exons 11 and 13, which probably led to the activation 
of c-KIT. The authors detected no influence of KIT mutations on both disease-
free and overall survival (34). As reported by several authors, therapeutic c-KIT 
blockade could be useful in the treatment of PMM patients with activating KIT 
mutation (35–37). More precisely, Antonescu et  al. reported that 15% of AM 
show the c-KIT L576P mutation that is particularly associated with sensitivity to 
imatinib in vitro (31). Therefore, the evaluation of c-KIT mutations in PMM 
patients could be extremely useful, although the role of this mutation in the 
prognosis is still under debate.
Furthermore, Omholt et  al. reported that mutations in the KIT, NRAS, and 
BRAF genes did not lead to activation of the ERK and Akt pathways in PM, 
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suggesting that other mechanisms, including mutation of the PIK3CA oncogene 
(encoding the catalytic subunit p110ms, including mutation of the ill under debate. 
KIT mutation in PTEN tumor suppressor gene may promote the activation of the 
ERK and Akt pathways in PMM (30). In contrast to CM, RAS mutation, especially 
in codon 61 of the NRAS, is rarely detected in AM. Indeed, it has been demon-
strated that elevated level of NRAS mutations were linked to UV radiation (38).
CLINICAL FEATURES AND INSTRUMENTAL DIAGNOSIS
A self-assessment of the skin plays a pivotal role in the early diagnosis of mela-
noma. However, when pigmented lesions are located on hidden areas, their 
assessment becomes more difficult. Accordingly, due to the hidden location and 
lack of early symptoms, the diagnosis of AM is usually delayed, with a poor prog-
nosis. According to a recent European study involving 444 patients with mucosal 
melanomas, AM was associated with the poorest prognosis (39). In this study, the 
authors related this poor prognosis to a propensity of AM to develop distant and 
brain metastases (39).
The main reasons that lead to a diagnosis of AM are the late and nonspecific 
signs and symptoms, which occur usually when tumoral masses are large (3–4 cm) 
(40, 41), and when the neoplasia involves the rectum, anus, or both sites, extend-
ing within 6 cm from the anal rim (40, 41). The most common clinical presenta-
tions of AM are changes in bowel habits, bowel obstruction, rectal bleeding, anal 
pain, and/or rectal tenesmus. These features are often associated with a mass that 
can prolapse through the anus (40, 41).
Clinically, AMs are polypoid lesions, mostly ulcerated and not pigmented, 
with an irregular surface, sometimes showing black or brown spots (Figure 1) (42). 
AM is often bloody and covered with mucinous/fibrinous material. The frequent 
amelanotic presentation of AM means that neoplasms of other origins, such as 
non-Hodgkin lymphoma, adenocarcinoma, and sarcoma, should be considered in 
the differential diagnosis (42). Nevertheless, due to the nonspecific clinical mani-
festations reported by the patients, AM is often misdiagnosed, masquerading as 
more common diseases of the lower gastrointestinal tract (such as adenomatous 
polyps, hemorrhoids, or rectal ulcers), resulting in delayed diagnosis (42). For 
these reasons, the lack of a clinical specificity for AM requires accurate and objec-
tive instrumental investigations, including rectal examination and investigations 
such as endoscopic ultrasonography and proctosigmoidoscopy. It is important to 
emphasize that there are no standardized diagnostic protocols for AM, unlike 
other common neoplasms of the large intestine (43).
Considering the lack of standardized diagnostic protocol for investigating pos-
sible AM, as there are for colorectal cancer, the identification of more appropriate 
and accurate diagnostic methods would allow for greater diagnostic accuracy and 
improvement of sensitivity and specificity of the endoscopic investigations. In this 
regard, proctosigmoidoscopy allows for macroscopic identification and character-
ization of the mass. A suspicion of AM is usually present in case of a mucosal 
lesion that invades the dentate line, and which has brown and dark spots on 
the  surface. In the absence of the abovementioned potential diagnostic criteria 
(melanin is present in only 30% of cases), histologic and immunohistochemical 
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evaluation (using HMB-45, S-100, Melan-A, and Vimentin) are indicated. In this 
regard, many authors emphasize the importance of performing multiple biopsies 
in order to avoid inconclusive histological characterizations (2, 9).
Finally, it is emphasized to use endoscopic ultrasounds and magnetic resonance 
imaging (MRI), to supplement colonoscopy in preoperative settings, allowing for 
the evaluation of the bowel wall in all five layers, assessing tumor infiltration, 
radial extension, and the total thickness of the neoplasia (2, 9). Ultrasonography 
allows the possibility for immediate biopsy in order to characterize suspicious 
loco-regional lymph nodes.
PATHOLOGY
As reported above, because of hidden location and lack of early symptoms, 
diagnosis of a mucosal melanoma is usually delayed, and many lesions are ulcer-
ated at the time of diagnosis, which associates with worse prognosis. It can also 
be difficult to differentiate between primary and metastatic disease. Usually, the 
absence of junctional changes in an ulcerated lesion does not preclude the pos-
sibility that the lesion is a primary melanoma (42, 44). In this regard, the typical 
amelanotic appearance of many AMs makes the diagnosis even more difficult 
(42,  44). Indeed, while pigmented lesions of the anorectal tract are always 
Figure 1 Anorectal melanoma. Courtesy of Dr. Fabrizio Gabrielli.
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highly suspect for melanoma, when pigment is absent, even microscopically, the 
diagnosis is more difficult and only an immunohistological examination can 
help reach a diagnosis.
There are four histologic types of AM. These include the epithelioid AM, the 
spindle-cell AM, the lymphoma-like AM, and the pleomorphic AM (44). The 
mitotic rate is usually about 2.82 mitotic figures per high-power field, ranging 
between 0.5 and 5.5 per high-power field, and without showing a correlation 
with the morphologic features or pigmentation (44).
The lymphoma-like AM, the spindle-cell AM, and the pleomorphic AM are 
often confused with a nonmelanocytic malignancy. Indeed, spindle-cell AM can 
be easily misdiagnosed for a gastrointestinal stromal tumor of the rectum. For this 
reason, an accurate immunohistochemical analysis plays a pivotal role in the 
 diagnosis of AM.
On immunohistochemistry, the cell population of AM usually shows a strong 
positivity to S100—a protein highly sensitive for melanocytic differentiation. 
However, given the lack of specificity, it is used primarily as a screening 
tool. Indeed, S-100 is present in many conditions, including nerve sheath tumors, 
 gliomas, neuroendocrine cells, melanocytic proliferations, some histiocytic prolif-
erations, langerhans cells, and also rarely in poorly differentiated carcinomas. AM 
usually stains for Melan-A, tyrosinase, and HMB-45, although there is often a 
variability in strength and distribution (44). HMB-45 and Melan-A also stain other 
tumors with melanocytic differentiation (e.g. angiomyolipomas, lymphangioleio-
myomatosis, and clear-cell myomelanocytic tumors); regardless, they have high 
specificity for melanocytic lesions, although their sensitivity is lower than S100. 
In fact, Melan-A and HMB-45 commonly fail to stain spindle-cell melanoma, 
often leading to diagnostic pitfalls (44). For the same reasons, anti-tyrosinase anti-
bodies, although they are considered melanocyte-specific (targeting the tyrosinase 
enzyme needed early in the cascade to create melanin pigment), are uncommonly 
present in cutaneous spindle-cell-type melanomas.
Usually AM is negative for pan-cytokeratin. Accordingly, it is important 
to remember that up to 10% of melanomas can show an expression of a kera-
tin  and/or epithelial marker (above all CAM5.2 and epithelial membrane 
 antigen)  (44). Accordingly, a misdiagnosis with a poorly differentiated rectal 
carcinoma is possible. Finally, another pitfall may be the positivity to carcino-
embryonic antigen when using polyclonal antibodies (44). Finally, c-Kit is posi-
tive in about 75% of AMs. c-Kit is a transmembrane tyrosine kinase receptor 
that plays a role in the development and proliferation of melanocytes, above all 
in mucosal sites (44).
STAGING
For a long time, AMs, as well as the other primary gastrointestinal melanomas, 
have been considered as metastatic melanomas (15). In fact, as reported above, 
the diagnosis of primary AM is often difficult to perform. However, some caution 
can aid in accurate diagnosis.
In order to consider a gastrointestinal melanoma as a primary melanoma, the 
following points must be satisfied: the presence of atypical melanocytes along the 
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basal epithelium in a histological sample, the absence of melanomas elsewhere, no 
history of metastatic melanoma, no previous regressed melanocytic lesions, nega-
tive history for skin lesion previously removed without histological examination, 
negative ophthalmological examination, negative esophagogastroduodenoscopy, 
negative colonoscopy (ignoring the suspect anorectal lesion), negative genital exam-
inations, and negative oropharyngeal and rhinopharyngeal examinations (18).
After reaching the diagnosis of primary AM, it is important to remember that 
AM has a poor overall survival (5 years; 10–20%). This is unchanged over the 
years due to the rarity of the neoplasm, which inhibits the development of stan-
dardized diagnostic and therapeutic protocols. Regardless of poor prognosis, AM 
is also related to various factors, including perineural invasion, rectal wall infiltra-
tion, nodal involvement, and distance metastases. In 2013, Bello et al. examined 
the clinical relevance of the location of origin of AM as a prognostic factor and, in 
a sample of 96 patients (41 with anal melanoma, 32 with AM, and 23 with rectal 
melanoma), found that lesions distal to the dentate line were more likely to recur 
with lymph-nodal involvement, which may represent differences in nodal drain-
age. However, the authors concluded that there were no differences in the long-
term prognosis, which remained poor for all cases of AM (45). At present, there is 
no staging available for primitive mucosal melanomas of the gastrointestinal tract 
which provides prognostic value.
Generally, the growth of AM closely resembles the nodular pattern of its cuta-
neous counterpart. This feature explains it poor survival and several reports have 
corroborating data that link survival most closely with tumor thickness. Patients 
with AM with a thickness ≤2 mm have better survival than patients with lesions 
>2 mm (46, 47). Regarding tumor size, Goldman et  al. found a correlation 
between overall survival and tumor size, showing greater overall survival for 
patients with tumors ≤2 cm (48). Unfortunately, because of the typical delay in 
the diagnosis, the vast majority of AM presents to clinicians as large, polypoid 
tumors with a thickness >2 mm, a tumor size >2 cm, and nodal involvement. 
According to these considerations, Breslow depth alone is of little use in the stag-
ing of the majority of primary AM. The relative consequences are that most 
authors advocated continued use of the clinical staging system developed for CM, 
where stage I is clinically localized disease, stage II is regional lymph-nodal 
 disease, and stage III is disseminated disease (46–51). However, two alternatives, 
based on the 7th American Joint Committee on Cancer (AJCC) staging system, 
might be applicable to AM: tumor node metastasis (TNM) staging of rectal cancer 
(rectal TNM) and tumor node metastasis of anal canal cancer (anal TNM) (52). 
Rectal TNM is based on the depth of tumor invasion into or beyond the wall 
of the rectum (T), number of regional lymph nodes involved (N), and status of 
distant metastases (M) (52). Anal TNM differs from rectal TNM in terms of tumor 
size (T) and status of regional or systemic LN involvement (N) (52). Staging 
 systems for AM are summarized in Table 2.
Mucosal infiltration is critically related to the presence of lymph nodes metas-
tases (>40%) and, consequently, to distant metastases, especially in the lung and in 
the liver (>90% in case of nodes neoplastic involvement). In 2006, Podnos et al., 
in a study of the Surveillance, Epidemiology, and End Results (SEER) database, 
found that in 126 AMs the extent of disease was statistically related with the poor-
est overall survival among mucosal melanomas (53). Recently, Iddings et al. found 
that lymph-nodal involvement is an important prognostic feature in AM (50). At 
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the same time, Chae et al., while attempting to develop a classification system for 
AM, highlighted and confirmed the predictive value of the number of regional 
lymph nodes involved (52). Unfortunately, detection of lymphatic drainage in the 
anal region is particularly difficult, due to the presence of 10 different lymphatic 
pathways. Inguinal/iliac or perirectal lymph nodes are most commonly involved in 
AM. Consequently, 18F-FDG-PET/CT and contrast-enhanced CT have been 
mainly studied for the evaluation of loco-regional and systemic involvement in AM 
patients. In this regard, PET/CT is superior for staging these patients, especially for 
loco-regional and systemic neoplastic involvement, and to plan the best surgical 
treatment for individual cases.
TREATMENT
The literature reports surgery as the most effective treatment for AM. However, 
assuming an adequate preoperative staging, which accurately highlights localiza-
tion of the disease, surgery does not result in real improvement of the overall 
survival. Indeed, there is no evidence regarding the benefits of surgery types. 
Many authors underline that abdominoperineal resection (APR) does not appear 
to be associated with improved survival compared to a local excision; on the con-
trary, APR seems to be related to a better disease-free survival with major control 
of loco-regional disease but without effectiveness in metastatic disease (54, 55). 
Long-term outcome does not seem to be influenced by the extent of surgical exci-
sions and, in many selected cases, local excisions are recommended in order to 
improve quality of life. APR has been compared to a wider excision in some stud-
ies; one of these, evaluating a database of 143 patients, did not find any survival 
differences in patients treated with the two different surgical procedures (55). 
Tumors with thickness ≤1 mm can undergo local sphincter-saving resection with 
1 cm margin, and tumors with thickness between 1.01 and 4 mm can undergo 
local sphincter-saving resection with 2 cm margin.
The role of regional lymphadenectomy in the surgical treatment of AM is 
a subject of debate (20). Mesorectal, pelvic sidewall, and inguinal lymph nodes 
are at increased risk of involvement from anorectal lesions. For this reason, during 
APR, the mesorectal lymph nodes are resected together with the primary 
tumor  (20). However, contrary to Goldman et  al., Yeh et  al. found that nodal 
involvement in AM did not predict outcome in patients undergoing radical 
 resection (56). At the same time, bilateral inguinal lymphadenectomy in AM 
patients without palpable lymph nodes did not improve survival but increased the 
risk of complications. While elective lymph-nodal dissection should be consid-
ered only in case of clinically palpable disease (20), laparoscopic abdominal-per-
ineal resection can also be considered a feasible choice in case of respectable 
primary melanoma and clinically palpable lymph node metastases (55). Local 
primary disease control could be reached with adjuvant radiotherapy after surgi-
cal definitive resection and wide excision; on the contrary, loco-regional lymph 
node irradiation is controversial; indeed, this procedure seems to be related to a 
worsening of postoperative lymphedema (55).
Regarding systemic therapies, there is currently no consensus about the most 
appropriate treatment for this type of melanoma. Some protocols, previously 
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directed to patients with CMs, have been studied in the context of mucosal mela-
noma, including AM. Traditional chemotherapy seems to have similar efficacy to 
chemo-immunotherapies in terms of survival. Dacarbazine (a cytotoxic chemo-
therapy) is associated with a survival of 20% (20). However, many responses are 
partial, with a median response duration of only 4–6 months (20, 57). There are 
no standardized data supporting a survival benefit for dacarbazine 250 mg/m2/day 
intra venous (repeating the cycle every 3 weeks) versus placebo (20, 57). The ana-
logue of dacarbazine and temozolomide (with the dosage of 200 mg/m2/day orally 
for 5 days, repeating the cycle every 4 weeks) has the benefit of being available 
orally, showing also a lower rate of central nervous system relapse (20). Dacarbazine 
or temozolomide, in association with other agents, has demonstrated no advantage 
over single-agent chemotherapy in phase III trials (58). A multicenter case–control 
study, evaluating the effect of dacarbazine versus a four-drug combination known 
as Dartmouth regimen (dacarbazine, cisplatin, carmustine, and tamoxifen), showed 
that the Dartmouth regimen exhibited a marginally improved response rate (19%) 
over dacarbazine alone (10%), but without statistical significance. Regardless, both 
treatments showed a poor survival of 7 months (58). Finally, Singhal et al. reported 
the effectiveness of taxanes (as paclitaxel at 100 mg/m2/IV) + platinum (cisplatin at 
20 mg/m2 IV or carboplatin 2 mg/mL/min IV) with or without the use of metro-
nomic therapy, showing a median overall survival of 11 months (59).
Other treatments of historical significance consisted of immune mediators, 
such as interferon-α and interleukin-2 (IL-2). High dosages of IL-2 (consisting of 
22 mcg/kg, 33 mcg/kg, 36 mcg/kg, or 44 mcg /kg every 8 h for up to 14 consecutive 
doses or doses as clinically tolerated) showed a good response in metastatic CM (60). 
High doses of IL-2 can be performed as monotherapy or in combination with the 
conventional chemotherapy. Indeed, recently, IL-2 combined with ipilimumab (at 3 
mg/kg) showed effectiveness in AM patients with unresectable disease (60, 61).
With the advent of targeted therapy, a higher number of therapeutic choices 
are available; however, the treatment of AM remains an important challenge. As 
reported above, up to 40% of AM presents KIT mutation. Accordingly, identifying 
c-Kit mutation allows initiation of treatment with tyrosine kinase inhibitors (62). 
Sorafenib (400 mg orally twice daily) is a less specific antagonist on c-Kit than 
imatinib but has been shown to have some effect in a previous case report of 
AM (63). Subsequently, Knowles et al. found an improvement in metastatic AM 
patients treated with imatinib (400 mg orally twice daily until disease progression 
or unacceptable toxicity), concluding that patients with AM and with a positivity 
to c-Kit mutation could be considered for a treatment with tyrosine kinase inhibi-
tors (TKIs) (63). However, in case of brain metastases, the use of sorafenib and 
imatinib is not recommended, as these TKIs do not cross the blood–brain barrier. 
In these cases, it is advised to use dasatinib (100 mg twice daily), a potent c-Kit 
inhibitor, which has a better penetration in the central nervous system (7).
Currently, association of anti-BRAF antibody (as vemurafenib or dabrafenib) 
and MEK inhibitors (as cobimetinib or trametinib) are available for BRAF-positive 
metastatic CM; however, there are no data for metastatic AM. Because the percent-
age of AM with BRAF mutation is low, the use of vemurafenib and dabrafenib in 
AM is not currently a pivotal therapeutic option.
In 2016, Tan reported the case of a young man with a metastatic AM, treated 
with ipilimumab, who showed improvement of 5-months, until the patient 
showed signs of disease progression (64). Immune-checkpoint inhibitors such as 
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ipilimumab (antibody to cytotoxic T-lymphocyte-associated protein-4, CTLA4), 
nivolumab (anti-PD1 antibody), and pembrolizumab (anti-PD1 antibody) have 
been approved for the treatment of melanoma. Tokuhara et al. reported a success-
ful treatment with nivolumab in a 67-year-old Japanese man with metastatic (liver 
and bone) AM. The authors administered nivolumab at 2 mg/kg, showing a sig-
nificant reduction of liver and bone metastases, showing no recurrences after 
17 months of follow-up (65). Nivolumab and more generally anti-PD1 treatments 
seem to be a promising choice for the treatment of metastatic AM. Combined che-
motherapy, anti-BRAF therapy, TKIs, and immune-checkpoint inhibitors remain 
important therapeutic options for these patients (65, 66).
CONCLUSION
AM is a rare and aggressive malignancy. Patients usually present with advanced 
disease due to delayed diagnosis and intrinsic high aggressiveness of the malig-
nancy. Because of the rarity and biological heterogeneity of the malignancy, 
there is neither a standardized staging schema nor a standardized medical and/
or surgical therapy. Although combined chemotherapy, anti-BRAF therapy, 
TKIs, and immune-checkpoint inhibitors remain important therapeutic options 
for these patients, further studies are needed to improve survival and quality 
of life of AM patients.
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